Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Antiviral Res. 2019 Apr 7;167:25–34. doi: 10.1016/j.antiviral.2019.04.004

Table 2.

Assessment of Type I IFN and clinical chemistry following BDGR-4 dosing

Analyte** Vehicle* BDGR-4*
IFNα serum (pg/ml) 0 0
IFNα brain (pg/ml) 6 6
IFNβ serum (pg/ml) 0 0
IFN β brain (pg/ml) 0 0
Alkaline Phosphatase (ALP:U/L) 67.1±7.8 62.7±12.8
Alanine Aminotransferase (ALT: U/L) 28.3±8.4 23.0±4.9
Aspartate Aminotransferase (AST:U/L) 141.7±73.4 108±19.1
Blood Urea Nitrogen (BUN:mg/dL) 18.7±1.4 21.0±1.0
Glucose (mg/dL) 156.4±21.1 184.5±26.4
Total Protein (g/dL) 4.4±0.18 4.3±0.2
Calcium (mg/dL) 9.5±0.5 9.4±0.3
*

Mice were dosed with vehicle or BDGR4 (25mg/kg BID) by IP injections over 4 days.

**

Type I IFNs were measured in serum and brain homogenates using a multiplex Immunoassay with a lower limit of detection for IFNα of 2.81pg/ml and lower limit of detection for IFNβ of 3.39pg/ml). Results are represented as average ± S.D. n=4–10 samples.